News
Accuray inks 10-year cancer tech agreement, shares in focus
1+ hour, 44+ min ago (479+ words) Madison, May 15, 2026, 18: 07 (CDT) Accuray Incorporated announced late Friday it's entering a 10-year tie-up with the University of Wisconsin School of Medicine and Public Health. The two plan to work on customized cancer treatments with Accuray's Stellar adaptive radiation therapy platform....
Medicaid overhaul looks to lower hospital prices
4+ hour, 14+ min ago (49+ words) WHAS11 Medicaid overhaul looks to lower hospital prices To stream WHAS11 on your phone, you need the WHAS11 app. Download the WHAS11 app Next up in 5 Example video title will go here for this video Before You Leave, Check This Out...
Brainstorm Cell Therapeutics Announces First Quarter 2026 Financial Results And Provides Corporate Update
5+ hour ago (31+ words) Trading View Brainstorm Cell Therapeutics Announces First Quarter 2026 Financial Results And Provides Corporate Update More news from Reuters...
ARS Pharmaceuticals 2026 Q1 10-Q: Financial Results, neffy" Commercialization, and Key Risk Factors
5+ hour, 2+ min ago (135+ words) ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), headquartered in San Diego, California, has released its quarterly report for the period ending March 31, 2026. The company is focused on pharmaceutical preparations, notably the commercialization of its flagship product, neffy (intranasal epinephrine), and its European…...
Aquestive Biosciences Reviews First Quarter 2026 Financial Performance
26+ min ago (18+ words) Aquestive Biosciences executives detailed the company's first quarter 2026 financial outcomes and operational milestones during an earnings call....
BIIB Advances Alzheimer's Disease Drug Despite Study Missing Main Goal
9+ hour, 3+ min ago (287+ words) Shares of Biogen BIIB declined more than 6% yesterday after the company announced that it would move its experimental tau-targeting Alzheimer's disease (AD) drug, diranersen, into late-stage development despite the phase II CELIA study missing its primary endpoint. The primary endpoint…...
Sensei Biotherapeutics, Inc. Q1 2026 10-Q Filing: Financial Statements, Risk Factors, and Management Analysis
5+ hour, 31+ min ago (277+ words) Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), headquartered in Rockville, MD, has published its unaudited condensed consolidated financial statements for the quarter ended March 31, 2026. This quarterly report provides crucial insights into the company's financial health, capital position, and operational progress, all of…...
Galectin Therapeutics Q1 2026 Financial Report: Earnings, Balance Sheet, and Key Disclosures
5+ hour, 33+ min ago (366+ words) Minichart Galectin Therapeutics Q1 2026 Financial Report: Earnings, Balance Sheet, and Key Disclosures Galectin Therapeutics Inc. Q1 2026 Financial Results: Key Insights for Investors Galectin Therapeutics Inc. (GALT), a Nasdaq-listed biotechnology firm, has released its unaudited condensed consolidated financial statements for the quarterly period…...
NEXGEL Adds Sequence Executives to Board After Deal Financing
4+ hour, 41+ min ago (258+ words) LANGHORNE, PA " NEXGEL, Inc. (Nasdaq: NXGL) appointed Sequence Life Science executives Brian Kieser and Kevin Harris to its board following a recent financing tied to NEXGEL's acquisition of a degenerative disease business from Celularity Inc. Kieser, chief executive officer of…...
Uber Doc Health Technologies Announces Leadership Transition
1+ hour, 41+ min ago (20+ words) Boston, Massachusetts--(Newsfile Corp. - May 15, 2026) - Uber Doc Health Technologies Corp. (CSE: APPT) (FSE: 4 KL0), a direct-pay healthcare marketplace. .....